Skip to content

Raltegravir non-inferior to efavirenz: 48 week, phase III results

CD4 decline, death more likely if change from NNRTI regimen delayed

Is there a role for tropism testing in routine HIV care?

Once-daily darunavir (Prezista) approved for first-line use in United States

Maraviroc fails to make economic case for use by NHS in Scotland

Reduced dose atazanavir safe and effective in small Thai study

Resistance to darunavir related to pre-existing mutations

Higher levels of drug resistance seen after first-line NNRTI failure than boosted PI failure: meta-analysis

Low rate of spontaneous hepatitis C clearance in patients with HIV; early HIV treatment recommended for those with chronic hepatitis C infection